Table 5 Univariate and Multivariate Cox Regression for OS among patients of Breast Cancer with Liver Metastases in the FUSCC dataset

 21–40

1[Reference]

1[Reference]

 41–60

1.34 (1.11–1.62)

0.003*

1.38 (1.09–1.74)

0.006*

  > 60

1.39 (1.10–1.75)

0.005*

1.55 (0.86–2.80)

0.145

 Infiltrating duct carcinoma

1[Reference]

1[Reference]

 Lobular carcinoma

0.90 (0.56–1.43)

0.648

0.68 (0.41–1.14)

0.146

 Other

0.72 (0.60–0.87)

< 0.001*

1.05 (0.85–1.29)

0.661

 No

1[Reference]

1[Reference]

 Yes

0.40 (0.31–0.52)

< 0.001*

0.67 (0.29–1.52)

0.337

 No surgery

1[Reference]

1[Reference]

 Yes

2.33 (1.83–2.98)

< 0.001*

1.02 (0.50–2.09)

0.947

 No

1[Reference]

1[Reference]

 Yes

2.56 (1.99–3.28)

< 0.001*

1.51 (0.88–2.60)

0.135

 No

1[Reference]

1[Reference]

 Yes

1.33 (1.17–1.51)

< 0.001*

1.20 (1.04–1.39)

0.014*

 Unknown

0.77 (0.54–1.08)

0.122

0.67 (0.45–0.99)

0.046*

 First liver metastases

1[Reference]

1[Reference]

 Subsequent liver metastases

2.16 (1.90–2.46)

< 0.001*

1.58 (1.33–1.87)

< 0.001*

 0

1[Reference]

1[Reference]

 1

1.54 (1.30–1.83)

< 0.001*

1.16 (0.95–1.41)

0.15

 2

2.16 (1.80–2.59)

< 0.001*

1.56 (1.23–1.97)

< 0.001*

 3

2.57 (2.08–3.18)

< 0.001*

2.05 (1.51–2.79)

< 0.001*

 All 4

5.49 (3.56–8.47)

< 0.001*

4.59 (2.42–8.69)

< 0.001*

 HR+/HER2−

1[Reference]

1[Reference]

 HR+/HER2+

0.82 (0.68–0.98)

0.033*

1.02 (0.83–1.25)

0.851

 HR−/HER2+

0.84 (0.70–1.01)

0.067

1.13 (0.92–1.40)

0.242

 Triple-negative

1.83 (1.53–2.20)

< 0.001*

2.17 (1.78–2.63)

< 0.001*

 Unknown

1.11 (0.79–1.57)

0.544

1.63 (1.10–2.43)

0.015*